A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer

Daniel Dauch,Ramona Rudalska,Giacomo Cossa,Jean-Charles Nault,Tae-Won Kang,Torsten Wuestefeld,Anja Hohmeyer,Sandrine Imbeaud,Tetyana Yevsa,Lisa Hoenicke,Tatu Pantsar,P Bozko,Nisar P. Malek,Thomas Longerich,Stefan Laufer,Antti Poso,Jessica Zucman–Rossi,Martin Eilers,Lars Zender

A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer

2016

Daniel Dauch
Ramona Rudalska
Giacomo Cossa
Jean-Charles Nault
Tae-Won Kang
Torsten Wuestefeld
Anja Hohmeyer
Sandrine Imbeaud
Tetyana Yevsa
Lisa Hoenicke
Tatu Pantsar
P Bozko
Nisar P. Malek
Thomas Longerich
Stefan Laufer
Antti Poso
Jessica Zucman–Rossi
Martin Eilers
Lars Zender

In Trp53-mutated hepatocellular carcinoma, conformation-changing aurora kinase A inhibitors disrupt aurora kinase A–MYC interactions, resulting in MYC degradation and suppression of tumor growth.

Keywords:

Aurora Kinase A Protein
Drug
Aurora Kinase A
Hepatocellular carcinoma
Liver cancer
Aurora kinase
Cancer research
Aurora inhibitor
Medicine
Mutation
Biology
Cell cycle checkpoint
Oncogene Protein p21(ras)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

143

Citations